Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02440685
Other study ID # ASN002-101
Secondary ID
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date May 2015
Est. completion date July 2018

Study information

Verified date May 2023
Source Asana BioSciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.


Description:

The study will be conducted in two parts. Part A is a dose escalation study to determine a safe and tolerable dose of ASN002 for subjects with relapsed or refractory lymphoma, or advanced solid tumors. Part A will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling. Subjects in Part B will enroll subjects with four types of lymphoma Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Peripheral T-cell lymphoma (PTCL). Additional groups of subjects with Myelofibrosis (MF) and Chronic Lymphocytic Leukemia (CLL) will be enrolled. Subjects will be treated with the highest safe and tolerable dose determined in Part A of the study to determine preliminary efficacy. Subjects may continue to receive ASN002 for up to 1 year in the absence of severe side effects or disease progression.


Recruitment information / eligibility

Status Terminated
Enrollment 51
Est. completion date July 2018
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent obtained prior to any study-related procedure being performed; - Male or female subjects at least 18 years of age at the time of consent; - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; - Recovered from the reversible effects of prior antineoplastic therapy (with the exception of alopecia and Grade 1 neuropathy). - Screening blood counts of the following: Absolute neutrophil count = 1000/µL, Platelets = 75,000/µL, Hemoglobin = 8 g/dL (with transfusion support); - Screening chemistry values of the following: Alanine aminotransferase (ALT) and aspartate transaminase (AST) = 3.0 × upper limit of the normal (ULN), total bilirubin = 1.5 × ULN, Creatinine = 1.5 × ULN; - At screening, life expectancy of at least 3 months; - Subject is willing and able to comply with all protocol required visits and assessments; - Male and female subjects of child-bearing potential must agree to use medically acceptable methods of birth control throughout the study and for thirty (30) days after the last dose of study medication. - (Part A only) Histologically or cytologically confirmed metastatic and/or advanced solid tumors or lymphomas for which no standard therapy exists, or who are not eligible for standard treatment. Subjects must have received at least one prior therapy for their malignancy; - (Part B only) Histologically confirmed DLBCL/MCL/FL/PTCL/MF/CLL on the basis of excisional lymph node or extranodal tissue biopsy; diagnosis of relapsed/refractory disease defined as 1) recurrence of disease after a Complete Response (CR), or 2) Partial Response (PR), Stable Disease (SD) at completion of treatment regimen preceding entry into study, subjects must not be candidates for standard therapy, subjects who have not received Stem Cell Translplant (SCT) must be ineligible to receive SCT. Exclusion Criteria - Have received prior chemotherapy regimens within 4 weeks of Day 1; - Have received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1; - Have had major surgery within 30 days prior to the start of Day 1; - Received any investigational treatment within 4 weeks prior to the start of study medication; - Have had an infection requiring the use of parenteral antibiotics within 14 days prior to the start of Day 1; - Have known central nervous system metastasis or Central Nervous System lymphoma; - Is receiving high dose corticosteroids (>10 mg prednisone daily or equivalent); - Has known bleeding diathesis that would be a safety risk; - Has a history of other malignancy within the 3 years prior to screening, except adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ; - Has difficulty swallowing medications, or known history of malabsorption syndrome; - Has a serious concurrent medical condition, such as: congestive heart failure New York Heart Association (NYHA) class III or IV or uncontrolled hypertension at screening, 12-Lead electrocardiogram (ECG) abnormalities considered by the investigator to be clinically significant including myocardial infarction, angioplasty, or cardiac stent placement within the last 6 months, HIV infection, known Hepatitis B or C infection. Subjects at high risk for Hepatitis B or C infection should have serology testing to rule out infection, a medical condition requiring the therapeutic use of anticoagulants. - Known hypersensitivity to ASN002 or its excipients; - Prior participation, i.e., receipt of study medication, in this study; - Any condition that, in the opinion of the investigator, would impair the subject's ability to comply with study procedures; - Female subjects that are pregnant or lactating. - Part B only: Prior treatment with SYK or Janus Kinase (JAK) inhibitors, except MF subjects.

Study Design


Related Conditions & MeSH terms

  • B-Cell Chronic Lymphocytic Leukemia
  • B-Cell Leukemia, Chronic
  • B-Lymphocytic Leukemia, Chronic
  • Cancer
  • Chronic Disease
  • Chronic Idiopathic Myelofibrosis
  • Chronic Lymphocytic Leukemia
  • Idiopathic Myelofibrosis
  • Leukemia
  • Leukemia, B-Cell
  • Leukemia, Lymphocytic, Chronic
  • Leukemia, Lymphocytic, Chronic, B Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Malignant
  • Lymphoma, Mantle-Cell
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T Cell, Peripheral
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral
  • Myelofibrosis
  • Neoplasm
  • Peripheral T-Cell Lymphoma
  • Primary Myelofibrosis
  • T-Cell Lymphoma, Peripheral
  • Tumor

Intervention

Drug:
ASN002 Dose Escalation
Multiple ascending doses of ASN002 assigned by cohort
ASN002 RD
Recommended dose of ASN002 from Part A

Locations

Country Name City State
Argentina Hospital Universitario Austral Buenos Aires Derqui, Pilar
Argentina Instituto Alexander Fleming Ciudad Autonoma de Buenos Aires
United States University of Michigan Ann Arbor Michigan
United States Winship Cancer Institute - Emory Atlanta Georgia
United States Gabrail Cancer Center Canton Ohio
United States Virginia Cancer Specialists Fairfax Virginia
United States START - Midwest Grand Rapids Michigan
United States MD Anderson Cancer Center Houston Texas
United States University of Mississippi Medical Center Jackson Mississippi
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States South Texas Accelerated Research Therapeutics San Antonio Texas
United States University of California, San Francisco San Francisco California
United States Arizona Oncology Tempe Arizona

Sponsors (1)

Lead Sponsor Collaborator
Asana BioSciences

Countries where clinical trial is conducted

United States,  Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate Due to the early termination of the study, data for efficacy endpoints were insufficient for the planned efficacy analyses. First 29 days
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients